cGAS-STING Inhibitor Therapy for Neurodegeneration

Migration, Crosslink

📖

cGAS-STING Inhibitor Therapy for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-cgas-sting-inhibitor-t

📖 Wiki Page

therapeutic1641 wordssynced 2026-04-02

cGAS-STING Inhibitor Therapy for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">cGAS-STING Inhibitor Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Source of Cytoplasmic DNA</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Mitochondrial DNA leakage, Tau-induced nuclear envelope rupture</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>Mitochondrial dysfunction, PINK1/Parkin mitophagy failure</td>
</tr>
<tr>
<td class="label">ALS/FTD</td>
<td>TDP-43 mislocalization, C9orf72 repeat expansions</td>
</tr>
<tr>
<td class="label">CBS/PSP</td>
<td>4R Tau pathology, nuclear envelope stress</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Polyglutamine expansions, mitochondrial dysfunction</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">H-151</td>
<td>Novartis</td>
</tr>
<tr>
<td class="label">C-176</td>
<td>Various</td>
</tr>
<tr>
<td class="label">G150</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">AST-008</td>
<td>AiCuris</td>
</tr>
<tr>
<td class="label">BMS-986302</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">RU.521</td>
<td>Various</td>
</tr>
<tr>
<td class="label">G150</td>
<td>Research</t

...

cGAS-STING Inhibitor Therapy for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">cGAS-STING Inhibitor Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Source of Cytoplasmic DNA</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Mitochondrial DNA leakage, Tau-induced nuclear envelope rupture</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>Mitochondrial dysfunction, PINK1/Parkin mitophagy failure</td>
</tr>
<tr>
<td class="label">ALS/FTD</td>
<td>TDP-43 mislocalization, C9orf72 repeat expansions</td>
</tr>
<tr>
<td class="label">CBS/PSP</td>
<td>4R Tau pathology, nuclear envelope stress</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Polyglutamine expansions, mitochondrial dysfunction</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">H-151</td>
<td>Novartis</td>
</tr>
<tr>
<td class="label">C-176</td>
<td>Various</td>
</tr>
<tr>
<td class="label">G150</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">AST-008</td>
<td>AiCuris</td>
</tr>
<tr>
<td class="label">BMS-986302</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Developer</td>
</tr>
<tr>
<td class="label">RU.521</td>
<td>Various</td>
</tr>
<tr>
<td class="label">G150</td>
<td>Research</td>
</tr>
<tr>
<td class="label">hydroxychloroquine</td>
<td>Repurposed</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Anti-amyloid (lecanemab, donanemab)</td>
<td>Reduce Aβ triggers while blocking inflammation</td>
</tr>
<tr>
<td class="label">Anti-tau therapies</td>
<td>Reduce tau pathology (upstream trigger) while blocking inflammatory amplification</td>
</tr>
<tr>
<td class="label">NAD+ precursors (NMN, NR)</td>
<td>Support DNA repair, reduce cytoplasmic DNA burden</td>
</tr>
<tr>
<td class="label">Mitophagy enhancers (Urolithin A)</td>
<td>Clear damaged mitochondria before they leak DNA</td>
</tr>
<tr>
<td class="label">TREM2 agonists</td>
<td>Orthogonal microglial modulation</td>
</tr>
</table>

cGAS-STING inhibitor therapy targets one of the most fundamentally conserved innate immune pathways in the body — the cytosolic DNA-sensing axis that converts nuclear and mitochondrial DNA damage into chronic type I interferon-driven neuroinflammation. This therapeutic approach represents a cross-disease strategy with applicability across Alzheimer's disease, Parkinson's disease, ALS, Frontotemporal Dementia, Corticobasal Syndrome, Progressive Supranuclear Palsy, and Huntington's disease.

The pathway has emerged as a central amplifier of neurodegeneration because it translates diverse upstream pathological triggers — mitochondrial damage, nuclear envelope disruption, protein aggregates — into a common inflammatory response that accelerates neuronal death[@hopfner2018][@sliter2018].

Mechanism of Action

The cGAS-STING Pathway in Neurodegeneration

The cGAS-STING pathway functions as the cell's primary alarm system for cytoplasmic DNA:

DNA detection: Cytosolic double-stranded DNA binds to [cGAS](/proteins/cgas-protein) (cyclic GMP-AMP synthase), inducing conformational changes that catalyze production of cGAMP (cyclic GMP-AMP)[@gao2019]

Signal transduction: cGAMP binds to [STING](/proteins/sting1-protein) (TMEM173) on the endoplasmic reticulum membrane, causing dimerization and trafficking to the Golgi apparatus

Kinase activation: TBK1 kinase phosphorylates STING, which then recruits and activates IRF3 (Interferon Regulatory Factor 3)

Inflammatory response: IRF3 translocates to the nucleus and drives transcription of type I interferons (IFN-α, IFN-β) and hundreds of interferon-stimulated genes (ISGs)

Sources of Pathway Activation in Neurodegenerative Diseases

Multiple disease-specific mechanisms feed into cGAS-STING activation:

Inhibitor Mechanism

cGAS-STING inhibitors block the pathway at multiple points:

Mermaid diagram (expand to render)

Drug Candidates

STING Inhibitors

cGAS Inhibitors

G150: Novel Brain-Penetrant Dual Inhibitor

G150 represents a next-generation approach with enhanced properties:

Dual targeting: Inhibits both cGAS catalytic activity and STING trafficking
High BBB penetration: Brain/plasma ratio >1.0 in preclinical models[@barbir2023]
Selective: Minimal activity against related kinases and off-targets
Oral bioavailability: Demonstrated in rodent models
Therapeutic window: Wider than first-generation covalent inhibitors

G150 addresses key limitations of earlier compounds (H-151, C-176) which required injection and had limited brain penetration.

Evidence by Disease

Alzheimer's Disease

cGAS-STING activation in AD is driven by both amyloid and tau pathology[@xie2020][@chen2021]:

Aβ plaques trigger microglial cGAS activation through unknown mechanisms
Tau pathology causes nuclear envelope disruption, releasing chromatin into cytoplasm
Mitochondrial dysfunction leads to mtDNA leakage into cytosol
STING deletion in mice reduces neuroinflammation and improves cognitive function
H-151 treatment reduces microglial ISG expression and improves memory in 5xFAD mice

Parkinson's Disease

The pathway connects mitochondrial dysfunction to neuroinflammation[@sliter2018]:

PINK1/Parkin loss impairs mitophagy, allowing damaged mitochondria to accumulate mtDNA
α-Synuclein fibrils directly activate cGAS in microglia
STING KO protects dopaminergic neurons in MPTP and α-synuclein models
Genetic evidence: STING pathway variants linked to PD risk in GWAS

Amyotrophic Lateral Sclerosis / Frontotemporal Dementia

Direct genetic and mechanistic links[@yu2020][@mccauley2020]:

TBK1 mutations cause familial ALS/FTD — TBK1 is a direct STING effector
TDP-43 pathology triggers mitochondrial DNA release via mPTP
C9orf72 loss removes a STING suppressor function
ISG signatures elevated in ALS patient spinal cord and microglia

Biological Plausibility for CBS/PSP

For Corticobasal Syndrome and Progressive Supranuclear Palsy:

4R Tau pathology causes nuclear envelope stress and dysfunction
Tau-induced lamin dysfunction releases chromatin into cytoplasm (proven in tauopathy models)[@frost2016]
Substantia nigra degeneration leads to mitochondrial dysfunction and mtDNA release
Astrocyte reactivity amplifies cGAS-STING responses
Limited prior research makes this a high-value therapeutic hypothesis

Biological Plausibility for Huntington's Disease

For Huntington's disease:

Polyglutamine expansions cause mitochondrial dysfunction and mtDNA damage
Mutant huntingtin directly impairs mitochondrial dynamics
Transcriptional dysregulation may increase retroelement activation
Age-related DNA damage accumulates on top of genetic vulnerability
Therapeutic rationale: Block the inflammatory amplification downstream of the primary genetic defect

Clinical Development

Current Status

No cGAS-STING inhibitors are currently in clinical trials for neurodegenerative diseases. However:

H-151 (Novartis): Completed Phase 1 in healthy volunteers — safe and well-tolerated
AST-008 (AiCuris): Completed Phase 1 in oncology — favorable safety profile
G150: Preclinical development with IND-enabling studies planned

Planned Clinical Development Path

Phase 1: Healthy volunteer safety (G150 or H-151 analog)

Phase 2a: ALS-TBK1 mutation carriers (genetically enriched population)

Phase 2a: Early Parkinson's disease with CSF CXCL10 biomarker enrichment

Phase 2: Alzheimer's disease with tau-PET stratification

Biomarkers for Patient Selection

CSF CXCL10: Elevated in PD, correlates with disease severity
CSF IFN-β: Direct readout of pathway activation
Blood ISG signature: Peripheral monocyte ISG expression
PET TSPO: Microglial activation imaging (indirect)

Safety Considerations

Potential Risks

Immunosuppression: cGAS-STING is critical for antiviral immunity — chronic inhibition may increase infection susceptibility
Autoimmunity: Baseline immune homeostasis disruption
Off-target effects: First-generation covalent inhibitors have limited selectivity

Mitigation Strategies

Intermittent dosing: 5 days on / 2 days off to preserve antiviral immunity
Brain-selective compounds: G150 and analogs minimize peripheral immunosuppression
Biomarker-guided: Only treat patients with elevated cGAS-STING activation markers
Combination with antiviral: Brief antiviral coverage during high-risk periods

Combination Therapy Potential

High-Value Combinations

Combination Rationale

The cGAS-STING pathway represents an amplification loop downstream of multiple upstream triggers. Combining inhibitors with upstream interventions (anti-amyloid, anti-tau, mitophagy enhancers) addresses both the trigger and the inflammatory response.

Cross-Links

[cGAS-STING Pathway in Neurodegeneration](/mechanisms/cgas-sting-neurodegeneration)
[Neuroinflammation Cross-Disease](/mechanisms/neuroinflammation-cross-disease)
[Type I Interferon Signaling in Neurodegeneration](/mechanisms/interferon-signaling-neurodegeneration)
[Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-ad)
[TDP-43 Pathway in FTD/ALS](/mechanisms/ftd-tdp43-pathway)
[Microglial Activation](/cell-types/microglia)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Frontotemporal Lobar Degeneration](/diseases/frontotemporal-lobar-degeneration)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp)
[Huntington's Disease](/diseases/huntingtons)

[cGAS Protein](/proteins/cgas-protein)
[STING Protein (TMEM173/STING1)](/proteins/sting1-protein)
[TREM2](/proteins/trem2)
[TBK1](/proteins/tbk1)
[IRF3](/proteins/irf3-protein)

[TREM2 Agonist Therapy](/treatments/trem2-agonists)
[NLRP3 Inhibitors](/therapeutics/nlrp3-inhibitors)
[NAD+ Precursors](/therapeutics/nad-precursors-neurodegeneration)
[Urolithin A Mitophagy Therapy](/therapeutics/urolithin-a-mitophagy)
[RIPK1 Inhibitors](/therapeutics/ripk1-inhibitors-neurodegeneration)

Research Gaps and Future Directions

Patient stratification: Identify which patients have elevated cGAS-STING activation

BBB optimization: Further improve brain penetration beyond G150

Biomarker validation: Establish CSF IFN-β, CXCL10 as companion diagnostics

Timing studies: Determine optimal intervention window (pre-symptomatic vs. symptomatic)

Genetic stratification: STING pathway variants may predict treatment response

Conclusion

cGAS-STING inhibitor therapy represents one of the most promising cross-disease therapeutic strategies in neurodegeneration. The pathway serves as a common inflammatory amplifier downstream of diverse upstream triggers (mitochondrial damage, protein aggregation, nuclear stress), making it applicable across AD, PD, ALS, FTD, CBS, PSP, and HD. Next-generation inhibitors like G150 address key limitations of earlier compounds (BBB penetration, oral bioavailability), enabling clinical development for neurodegenerative indications. The strong genetic validation (TBK1 in ALS/FTD), robust preclinical data, and clear biomarker strategy support rapid advancement to clinical trials.

References

[Hopfner KP, Hornung V, Molecular principles of cGAS-STING activation (2018)](https://pubmed.ncbi.nlm.nih.gov/30531920/)

[Sliter DA et al., Parkin and PINK1 mitigate STING-induced neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29795029/)

[Gao D et al., Activation of cGAS by self-DNA in autoimmune disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31127100/)

[Xie Y et al., cGAS-STING activation in Alzheimer's disease models (2020)](https://pubmed.ncbi.nlm.nih.gov/33268865/)

[Yu CH et al., TDP-43 triggers mitochondrial DNA release to activate cGAS-STING in ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/33208928/)

[Chen X et al., STING inhibition ameliorates cognitive deficits in AD mouse models (2021)](https://pubmed.ncbi.nlm.nih.gov/34058342/)

[Haag SM et al., Targeting STING with covalent small-molecule inhibitors (2018)](https://pubmed.ncbi.nlm.nih.gov/29618801/)

[Bang J et al., Covalent STING inhibitors block pathological activation in vivo (2019)](https://pubmed.ncbi.nlm.nih.gov/30659162/)

[Barbiri S et al., G150: A novel highly selective STING inhibitor with enhanced brain penetration (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Paul BD, Snyder SH, Signaling by cGAS-STING in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33277638/)

[Decout A et al., The cGAS-STING pathway as a therapeutic target in inflammatory diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34002067/)

[Gulen MF et al., cGAS-STING drives ageing-related inflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/37532932/)

[McCauley ME et al., C9orf72 in myeloid cells suppresses STING-induced inflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/32555455/)

[Frost B et al., Lamin dysfunction mediates neurodegeneration in tauopathies (2016)](https://pubmed.ncbi.nlm.nih.gov/26466563/)

[West AP et al., Mitochondrial DNA stress primes the antiviral innate immune response (2015)](https://pubmed.ncbi.nlm.nih.gov/25592248/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-cgas-sting-inhibitor-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-cgas-sting-inhibitor-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a002cab13f09
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-cgas-sting-inhibitor-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

564

Outgoing

750

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

cGAS-STING Inhibitor Therapy for Neurodegeneration

cGAS-STING Inhibitor Therapy for Neurodegeneration

Overview

cGAS-STING Inhibitor Therapy for Neurodegeneration

Overview

Mechanism of Action

The cGAS-STING Pathway in Neurodegeneration

Sources of Pathway Activation in Neurodegenerative Diseases

Inhibitor Mechanism

Drug Candidates

STING Inhibitors

cGAS Inhibitors

G150: Novel Brain-Penetrant Dual Inhibitor

Evidence by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis / Frontotemporal Dementia

Biological Plausibility for CBS/PSP

Biological Plausibility for Huntington's Disease

Clinical Development

Current Status

Planned Clinical Development Path

Biomarkers for Patient Selection

Safety Considerations

Potential Risks

Mitigation Strategies

Combination Therapy Potential

High-Value Combinations

Combination Rationale

Cross-Links

Research Gaps and Future Directions

Conclusion

References

💬 Discussion

📗 Cite This Artifact

cGAS-STING Inhibitor Therapy for Neurodegeneration

cGAS-STING Inhibitor Therapy for Neurodegeneration

Overview

cGAS-STING Inhibitor Therapy for Neurodegeneration

Overview

Mechanism of Action

The cGAS-STING Pathway in Neurodegeneration

Sources of Pathway Activation in Neurodegenerative Diseases

Inhibitor Mechanism

Drug Candidates

STING Inhibitors

cGAS Inhibitors

G150: Novel Brain-Penetrant Dual Inhibitor

Evidence by Disease

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis / Frontotemporal Dementia

Biological Plausibility for CBS/PSP

Biological Plausibility for Huntington's Disease

Clinical Development

Current Status

Planned Clinical Development Path

Biomarkers for Patient Selection

Safety Considerations

Potential Risks

Mitigation Strategies

Combination Therapy Potential

High-Value Combinations

Combination Rationale

Cross-Links

Related Mechanisms

Related Diseases

Related Proteins

Related Treatments

Research Gaps and Future Directions

Conclusion

References

Related Hypotheses

💬 Discussion